Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma

Next Previous
Trial Profile

Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tucatinib (Primary) ; Capecitabine; Trastuzumab; Trastuzumab
  • Indications Advanced breast cancer; Carcinoma; HER2 positive breast cancer; Male breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms H2C; HER2CLIMB
  • Sponsors Cascadian Therapeutics; Seagen

Most Recent Events

  • 22 Feb 2023 According to Seagen media release, TUKYSA is now reimbursed in Ontario, Manitoba, Saskatchewan. The reimbursement is based on the data from this study.
  • 06 Dec 2022 According to a Seagen media release, based on this trial TUKYSA is now authorized in British Columbia for reimbursement for the Treatment of Patients with Advanced or Metastatic HER2-Positive Breast Cancer.
  • 10 Sep 2022 This trial has been completed in Austria, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top